HEMLIBRA works differently than treatments you may have used in the past

HEMLIBRA is not an infusion of factor VIII. It's an injection that goes under your skin (subcutaneous) to help your blood clot.

HEMLIBRA acts like a bridge, bringing activated factor IX and factor X together. This enables the clotting process to continue without needing to replace factor VIII.

HEMLIBRA is an injection you take once weekly, every 2 weeks, or every 4 weeks as prescribed by your doctor.

HEMLIBRA offers steady and consistent levels between doses, so there's no need to adjust dosing based on activities.

HEMLIBRA has a half-life of 4 weeks*

Treatment will begin with a loading dose once weekly for 4 weeks to increase the levels of HEMLIBRA in your blood. When the loading dose is complete you will start your maintenance dose, which helps HEMLIBRA levels in your blood remain steady. Your healthcare provider will decide how often you should use your maintenance dose, which can be once weekly, every 2 weeks, or every 4 weeks.

Lower levels of HEMLIBRA in blood were expected in children less than 6 months old.

FVIII=factor VIII.  
*After multiple subcutaneous injections, the amount of time estimated for the body to clear half of HEMLIBRA from the blood is 4 weeks.

HEMLIBRA is a therapeutic antibody created to help blood clot

Therapeutic antibodies are molecules created in a laboratory to treat disease. Doctors have successfully used therapeutic antibodies as medicines for more than 30 years in cancer, multiple sclerosis, and asthma. HEMLIBRA received FDA approval in 2017 as prophylaxis for people with hemophilia A with factor VIII inhibitors and in 2018 as prophylaxis for people without factor VIII inhibitors.

You can learn more about how HEMLIBRA works here.

Clinical Studies

HEMLIBRA was studied in people with and without factor VIII inhibitors

More About How HEMLIBRA Works

Download our brochure to find out how HEMLIBRA works differently


The manufacturing process and Genentech's standards